Eliot Godofsky
Overview
Explore the profile of Eliot Godofsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola-Tompkins E, Donatacci L, et al.
HIV Clin Trials
. 2008 May;
9(2):73-82.
PMID: 18474492
Purpose: To evaluate the safety and antiviral activity of once-daily (qd) enfuvirtide (ENF) compared with twice daily (bid) ENF. Method: T20-401 was a phase 2, open-label, randomized, 48-week pilot study...
12.
Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, et al.
J Acquir Immune Defic Syndr
. 2007 Dec;
47(3):342-5.
PMID: 18091608
Objective: The aim of this study was to examine the influence of kidney disease and hemodialysis on the pharmacokinetics ofenfuvirtide. Design: An open-label, multicenter, parallel group study of HIV-1-infected patients...
13.
Jacobson I, Brown Jr R, Freilich B, Afdhal N, Kwo P, Santoro J, et al.
Hepatology
. 2007 Sep;
46(4):971-81.
PMID: 17894303
Unlabelled: This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in...
14.
Kuritzkes D, Jacobson J, Powderly W, Godofsky E, DeJesus E, Haas F, et al.
J Infect Dis
. 2004 Jan;
189(2):286-91.
PMID: 14722894
Background: We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against...